Award
National Cancer Institute 5R01CA276286-04
Understanding Immunotype, a Novel Biomarker for Checkpoint Blockade Resistance
Recipient
Not specified
Award Amount
$552,755.00
Ceiling
$552,755.00
Awarded
February 13, 2026
Identifier
5R01CA276286-04
The project aims to test the hypothesis that Immunotype-1 (IT-1) is a pan-cancer biomarker for immune checkpoint blockade resistance, involving phenotypic and functional characterization of immune cells, association with clinical outcomes, and response prediction to specific therapies.
Description
The project focuses on identifying a biomarker for resistance to immune checkpoint blockade in cancer therapy. The award is managed by the National Cancer Institute. The project involves clinical data analysis, immune profiling, and biomarker validation.